Literature DB >> 9851786

The acid-labile subunit of human ternary insulin-like growth factor binding protein complex in serum: hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic use in patients with growth hormone deficiency.

A Juul1, S Møller, E Mosfeldt-Laursen, M H Rasmussen, T Scheike, S A Pedersen, K W Kastrup, H Yu, J Mistry, S Rasmussen, J Müller, J Henriksen, N E Skakkebaek.   

Abstract

Circulating insulin-like growth factor-I (IGF-I) is predominantly bound in the trimeric complex comprised of IGF binding protein-3 (IGFBP-3) and acid-labile subunit (ALS). Circulating concentrations of IGF-I, IGFBP-3 and ALS are believed to reflect the GH secretory status, but the clinical use of ALS determination is not known. We therefore, determined the: 1) hepatosplanchnic release of ALS by liver vein catheterization (n=30); 2) 24-h diurnal variation of ALS (n=8); 3) normal age-related ranges of circulating ALS (n=1158); 4) diagnostic value of ALS in 108 patients with childhood-onset GH deficiency (GHD). We found: 1) no significant arteriovenous gradient over the liver ofALS, IGF-I, and IGFBP-3; 2) the diurnal variation of ALS was 12% (mean coefficient of variation percent); 3) ALS levels increased throughout childhood with maximal levels in puberty, with a subsequent decrease with age in adults; and 4) ALS levels were below -2 SD in 57 of 79 GHD patients (sensitivity 72%) and above 2 SD in 22 of 29 patients with normal GH response (specificity 76%), which was similar, compared with the diagnostic utility of IGF-I and IGFBP-3. Finally, our findings indicate that hepatic ALS production is not measurable by this approach or, alternatively, that the liver is not the primary source of circulating ALS, IGF-I, or IGFBP-3 in humans. In conclusion, we have provided extensive normal data for a novel ALS assay and found that circulating ALS levels exhibit minor diurnal variation. We suggest that ALS determination may be used in future classification of adults suspected of GHD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851786     DOI: 10.1210/jcem.83.12.5311

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation.

Authors:  H Yu; J Mistry; M J Nicar; M J Khosravi; A Diamandis; J van Doorn; A Juul
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

Review 2.  Assessment of serum IGF-I concentrations in the diagnosis of isolated childhood-onset GH deficiency: a proposal of the Italian Society for Pediatric Endocrinology and Diabetes (SIEDP/ISPED).

Authors:  G Federico; M E Street; M Maghnie; M Caruso-Nicoletti; S Loche; S Bertelloni; S Cianfarani
Journal:  J Endocrinol Invest       Date:  2006-09       Impact factor: 4.256

3.  Determining the normal range for IGF-I, IGFBP-3, and ALS: new reference data based on current internal standards.

Authors:  Diana-Alexandra Ertl; Andreas Gleiss; Susanne Sagmeister; Gabriele Haeusler
Journal:  Wien Med Wochenschr       Date:  2014-09-04

4.  Quantitative ontogeny of murine insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the IGF-related acid-labile subunit.

Authors:  David L Hwang; Phillip D K Lee; Pinchas Cohen
Journal:  Growth Horm IGF Res       Date:  2007-08-23       Impact factor: 2.372

5.  The Differential Hormonal Milieu of Morning versus Evening May Have an Impact on Muscle Hypertrophic Potential.

Authors:  Simon D Burley; Jayde Whittingham-Dowd; Jeremy Allen; Jean-Francois Grosset; Gladys L Onambele-Pearson
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

6.  Association of IGF1 with glycemic control and occurrence of severe hypoglycemia in patients with type 1 diabetes mellitus.

Authors:  Louise Færch; Anders Juul; Ulrik Pedersen-Bjergaard; Birger Thorsteinsson
Journal:  Endocr Connect       Date:  2012-06-21       Impact factor: 3.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.